Coenzyme Q10 and spinocerebellar ataxias

Raymond Y. Lo, Karla P. Figueroa, Stefan M. Pulst, Chi Ying Lin, Susan Perlman, George Wilmot, Christopher Gomez, Jeremy Schmahmann, Henry Paulson, Vikram G. Shakkottai, Sarah Ying, Theresa Zesiewicz, Khalaf Bushara, Michael Geschwind, Guangbin Xia, S. H. Subramony, Tetsuo Ashizawa, Sheng Han Kuo

Research output: Contribution to journalArticle

Abstract

The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association.

Original languageEnglish (US)
Pages (from-to)214-220
Number of pages7
JournalMovement disorders : official journal of the Movement Disorder Society
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

coenzyme Q10
Spinocerebellar Ataxias
Ataxia
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Huntington Disease
Vitamin E
Pharmaceutical Preparations
Longitudinal Studies
Health
Research

Keywords

  • Coenzyme Q10
  • Neurodegeneration
  • Spinocerebellar ataxias
  • Statins

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Lo, R. Y., Figueroa, K. P., Pulst, S. M., Lin, C. Y., Perlman, S., Wilmot, G., ... Kuo, S. H. (2015). Coenzyme Q10 and spinocerebellar ataxias. Movement disorders : official journal of the Movement Disorder Society, 30(2), 214-220. https://doi.org/10.1002/mds.26088

Coenzyme Q10 and spinocerebellar ataxias. / Lo, Raymond Y.; Figueroa, Karla P.; Pulst, Stefan M.; Lin, Chi Ying; Perlman, Susan; Wilmot, George; Gomez, Christopher; Schmahmann, Jeremy; Paulson, Henry; Shakkottai, Vikram G.; Ying, Sarah; Zesiewicz, Theresa; Bushara, Khalaf; Geschwind, Michael; Xia, Guangbin; Subramony, S. H.; Ashizawa, Tetsuo; Kuo, Sheng Han.

In: Movement disorders : official journal of the Movement Disorder Society, Vol. 30, No. 2, 01.02.2015, p. 214-220.

Research output: Contribution to journalArticle

Lo, RY, Figueroa, KP, Pulst, SM, Lin, CY, Perlman, S, Wilmot, G, Gomez, C, Schmahmann, J, Paulson, H, Shakkottai, VG, Ying, S, Zesiewicz, T, Bushara, K, Geschwind, M, Xia, G, Subramony, SH, Ashizawa, T & Kuo, SH 2015, 'Coenzyme Q10 and spinocerebellar ataxias', Movement disorders : official journal of the Movement Disorder Society, vol. 30, no. 2, pp. 214-220. https://doi.org/10.1002/mds.26088
Lo, Raymond Y. ; Figueroa, Karla P. ; Pulst, Stefan M. ; Lin, Chi Ying ; Perlman, Susan ; Wilmot, George ; Gomez, Christopher ; Schmahmann, Jeremy ; Paulson, Henry ; Shakkottai, Vikram G. ; Ying, Sarah ; Zesiewicz, Theresa ; Bushara, Khalaf ; Geschwind, Michael ; Xia, Guangbin ; Subramony, S. H. ; Ashizawa, Tetsuo ; Kuo, Sheng Han. / Coenzyme Q10 and spinocerebellar ataxias. In: Movement disorders : official journal of the Movement Disorder Society. 2015 ; Vol. 30, No. 2. pp. 214-220.
@article{28ccbb4b378649cabd00ae405d270bde,
title = "Coenzyme Q10 and spinocerebellar ataxias",
abstract = "The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association.",
keywords = "Coenzyme Q10, Neurodegeneration, Spinocerebellar ataxias, Statins",
author = "Lo, {Raymond Y.} and Figueroa, {Karla P.} and Pulst, {Stefan M.} and Lin, {Chi Ying} and Susan Perlman and George Wilmot and Christopher Gomez and Jeremy Schmahmann and Henry Paulson and Shakkottai, {Vikram G.} and Sarah Ying and Theresa Zesiewicz and Khalaf Bushara and Michael Geschwind and Guangbin Xia and Subramony, {S. H.} and Tetsuo Ashizawa and Kuo, {Sheng Han}",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/mds.26088",
language = "English (US)",
volume = "30",
pages = "214--220",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Coenzyme Q10 and spinocerebellar ataxias

AU - Lo, Raymond Y.

AU - Figueroa, Karla P.

AU - Pulst, Stefan M.

AU - Lin, Chi Ying

AU - Perlman, Susan

AU - Wilmot, George

AU - Gomez, Christopher

AU - Schmahmann, Jeremy

AU - Paulson, Henry

AU - Shakkottai, Vikram G.

AU - Ying, Sarah

AU - Zesiewicz, Theresa

AU - Bushara, Khalaf

AU - Geschwind, Michael

AU - Xia, Guangbin

AU - Subramony, S. H.

AU - Ashizawa, Tetsuo

AU - Kuo, Sheng Han

PY - 2015/2/1

Y1 - 2015/2/1

N2 - The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association.

AB - The aim of this study was to investigate the association between drug exposure and disease severity in SCA types 1, 2, 3 and 6. The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 319 participants with SCA1, 2, 3, and 6 from 12 medical centers in the United States and repeatedly measured clinical severity by the Scale for Assessment and Rating of Ataxia (SARA), the Unified Huntington's Disease Rating Scale part IV (UHDRS-IV), and the 9-item Patient Health Questionnaire during July 2009 to May 2012. We employed generalized estimating equations in regression models to study the longitudinal effects of coenzyme Q10 (CoQ10), statin, and vitamin E on clinical severity of ataxia after adjusting for age, sex, and pathological CAG repeat number. Cross-sectionally, exposure to CoQ10 was associated with lower SARA and higher UHDRS-IV scores in SCA1 and 3. No association was found between statins, vitamin E, and clinical outcome. Longitudinally, CoQ10, statins, and vitamin E did not change the rates of clinical deterioration indexed by SARA and UHDRS-IV scores within 2 years. CoQ10 is associated with better clinical outcome in SCA1 and 3. These drug exposures did not appear to influence clinical progression within 2 years. Further studies are warranted to confirm the association.

KW - Coenzyme Q10

KW - Neurodegeneration

KW - Spinocerebellar ataxias

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84922240709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922240709&partnerID=8YFLogxK

U2 - 10.1002/mds.26088

DO - 10.1002/mds.26088

M3 - Article

C2 - 25449974

AN - SCOPUS:84922240709

VL - 30

SP - 214

EP - 220

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 2

ER -